ArticleVaccines2023
PrEP Scale-Up and PEP in Central and Eastern Europe: Changes in Time and the Challenges We Face with No Expected HIV Vaccine in the near Future.
Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Interest in and Preference for Long-Acting Injectable Pre-exposure Prophylaxis Among Men Who Have Sex With Men, Trans* Individuals, and Cisgender Heterosexual Women: A Global Systematic Review and Meta-Analysis.Journal of acquired immune deficiency syndromes (1999) · 2025Pooled it
- Intimate Partner Violence Victimization and HIV PrEP Adherence Among Gay, Bisexual Men, and Other Men Who Have Sex with Men in Ukraine.AIDS and behavior · 2026Article
- Trends and Projected Burden of HIV/AIDS in Kazakhstan, 2010-2030: A Comparative Analysis Using GBD 2023 Estimates.Tropical medicine and infectious disease · 2026Article
- Stakeholders' perspectives on HIV prevention in the Czech Republic: a qualitative study.Frontiers in public health · 2026Article
- Pre-exposure prophylaxis against HIV infection among male population under perceived risk of sexually transmitted infections in Vojvodina, Serbia: a cross-sectional study on knowledge and attitudes.Frontiers in reproductive health · 2026Article
- Alcohol Use Disorder and HIV Risk in a National Survey of Men Who Have Sex with Men in Ukraine.International journal of behavioral medicine · 2025Article
- HIV Pre-exposure Prophylaxis (PrEP) Uptake and Persistence in Wartime Ukraine: Analysis of Data from a Scaled PrEP Program.AIDS and behavior · 2025Observational
- Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Control of HIV across the WHO European region: progress and remaining challenges.The Lancet regional health. Europe · 2025Review
- Sexually transmitted infections in the non-European Union and European Economic Area of the World Health Organization European Region 2021-2023.BMC public health · 2025Article
- Global burden of HIV, syphilis, and HBV infection among women of childbearing age and children under five: based on the Global Burden of Diseases Study 2021.Frontiers in public health · 2025Article
- In danger: HIV vaccine research and development in Europe.PLOS global public health · 2025Article
- The HIV epidemic in eastern Europe and central Asia in difficult times: a story of resilience and change.Journal of the International AIDS Society · 2024Article
- Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe.The Lancet regional health. Europe · 2023Review
- Epidemiology and determinants of reemerging bacterial sexually transmitted infections (STIs) and emerging STIs in Europe.The Lancet regional health. Europe · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 20 institutions in 23 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With no expected vaccine for HIV in the near future, we aimed to define the current situation and challenges for pre- and post-exposure prophylaxis (PrEP and PEP) in Central and Eastern Europe (CEE). The Euroguidelines CEE Network Group members were invited to respond to a 27-item survey including questions on PrEP (response rate 91.6%). PrEP was licensed in 68.2%; 95 centers offered PrEP and the estimated number on PrEP was around 9000. It was available in daily (40.1%), on-demand (13.3%), or both forms (33.3%). The access rate was <1−80%. Three major barriers for access were lack of knowledge/awareness among people who are in need (59.1%), not being reimbursed (50.0%), and low perception of HIV risk (45.5%). Non-occupational PEP was available in 86.4% and was recommended in the guidelines in 54.5%. It was fully reimbursed in 36.4%, only for accidental exposures in 40.9%, and was not reimbursed in 22.72%. Occupational PEP was available in 95.5% and was reimbursed fully. Although PrEP scale-up in the region has gained momentum, a huge gap exists between those who are in need of and those who can access PrEP. Prompt action is required to address the urgent need for PrEP scale-up in the CEE region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.